Trials / Completed
CompletedNCT00610454
Safety and Tolerability of Levetiracetam Intravenous 15 Minute Infusion in Subjects Suffering From Partial Onset Seizures
Trial Evaluating the Safety and Tolerability of Levetiracetam Intravenous 15-minute Infusion, Administered in b.i.d. Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 65 Years Suffering From Partial Onset Seizures
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 16 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Subjects receiving LEV as adjunctive therapy to 1 or 2 other AEDs for partial onset seizures and subjects who are temporarily unable to take oral LEV, may require alternative routes of administration. The purpose of this trial was to evaluate the safety and tolerability of 1000 to 3000 mg/day LEV administered as a 15-min IV infusion b.i.d. after switching from the same oral dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levetiracetam |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2004-08-01
- Completion
- 2004-08-01
- First posted
- 2008-02-08
- Last updated
- 2013-12-06
Source: ClinicalTrials.gov record NCT00610454. Inclusion in this directory is not an endorsement.